Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Antithrombin III therapy of angiogenesis-dependent diseases

13.12.2006
During growth, tumours secrete enzymes, which proteolytically cleave known proteins, such as collagen XVIII and antithrombin III (AT III), or alter their conformation (e.g. to latent AT III). The fragments formed in this way (cleavage products) show in vitro and in vivo antiangiogenic properties and function as negative regulators of an-giogenesis.

One approach is to manufacture these negative regulators, for example the antiangiogenic functioning cleavage products, in order to use these therapeutically with patients in the form of a pharmaceutical. This has already been realised in the case of endostatin, however with the disadvantage that the genetically modified proteins, depending on the expression system used, show no exact consensus and 100% effectiveness in comparison to naturally occurring cleavage products. The invention shows that antiangiogenic antithrombin III is also a cleavage product or protein with modified conformity derived from native antithrombin III. Since the tumour cells are capable of decomposing antithrombin or changing its conformation, the application of native antithrombin III in vivo leads to a reduction or a stoppage of growth through inhibition of the vascular growth. This means that native antithrombin III can also be directly applied in therapy. An expensive, complex and time-consuming separate approval as a medicinal product is not necessary, since native antithrombin III is a medicine that can already be found on the market for the treatment of inflammation reactions. Experiments show that antithrombin III leads to a reduction in the growth of the blood vessels and thereby a reduction of the tumour. It is very suitable for application in tumour angiogenesis. In vivo experiments with mice confirm this; a therapy with 50 mg/kg/day antithrombin III leads to a clear inhibition of angiogenesis through reduced microvessel density and finally causes a complete obstruction of the growth of the tumour.

Further Information: PDF

TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12

Contact
Dr. Peter Stumpf

info@technologieallianz.de | TechnologieAllianz e.V.
Further information:
http://www.technologieallianz.de/angebote.php?sort=sag&id=0847&lang=en
http://www.technologieallianz.de

More articles from Technology Offerings:

nachricht New Lithium Salts of Pentafluorophenylamide Anions as Electrolytes in Lithium Ionic Batteries
18.04.2017 | TechnologieAllianz e.V.

nachricht Gratings on glass surfaces
28.03.2017 | TechnologieAllianz e.V.

All articles from Technology Offerings >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Optical Coherence Tomography: German-Japanese Research Alliance hosted Medical Imaging Conference

19.11.2018 | Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

 
Latest News

When AI and optoelectronics meet: Researchers take control of light properties

20.11.2018 | Physics and Astronomy

Researchers use MRI to predict Alzheimer's disease

20.11.2018 | Medical Engineering

How to melt gold at room temperature

20.11.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>